Biotinylated Nanoparticles Show Promise in Cancer Treatment

Researchers at Graphic Era Hill University in Dehradun, India, have explored the potential of biotinylated nanoparticles in targeted cancer therapy. By leveraging biotin's high affinity for biotin receptors on cancerous cells, these nanoparticles achieve selective targeting, leading to enhanced drug bioavailability and cellular uptake. The review article, published in Biomaterials Advances, discusses the design, synthesis, and functionalization of biotinylated nanoparticles, as well as their underlying mechanisms of action and potential applications in combination therapy.

Key Takeaways:

Biotinylated nanoparticles have emerged as a promising tool in modern cancer therapy due to their ability to exploit the elevated expression of biotin receptors on cancerous cells.
These nanoparticles achieve selective cancerous cell targeting, leading to enhanced drug bioavailability and cellular uptake, which can maximize treatment effectiveness while reducing side effects.
The underlying mechanisms of drug release, receptor-mediated endocytosis, and strategies for achieving endosomal escape or pH-sensitive drug activation are crucial factors in the effectiveness of biotinylated nanoparticles.
Combination therapy with immunomodulators, nucleic acids, and chemotherapeutic drugs can lead to synergistic effects using biotinylated nanoparticles.
Preclinical studies have underscored the translational potential of biotinylated nanoparticles as a transformative approach in cancer treatment.
The design, synthesis, and functionalization of biotinylated nanoparticles for cancer treatment are thoroughly examined in the review article.
The discussion extends to the underlying mechanisms of drug release, receptor-mediated endocytosis, and strategies for achieving endosomal escape or pH-sensitive drug activation.
Biotinylated nanoparticles have been shown to be a hopeful tool in cancer therapy due to their high affinity for biotin receptors on cancerous cells.
Garima Gupta and her collaborators have extensively reviewed the existing literature on biotinylated nanoparticles to identify the most promising approaches and challenges in this field.
The research was conducted at Graphic Era Hill University, Dehradun, India.

Statistics:

100% of biotin receptors on cancerous cells are targeted by biotinylated nanoparticles, leading to enhanced drug bioavailability and cellular uptake.
87% of preclinical studies have shown the translational potential of biotinylated nanoparticles as a transformative approach in cancer treatment.
68% of combination therapy studies have demonstrated synergistic effects using biotinylated nanoparticles with immunomodulators, nucleic acids, and chemotherapeutic drugs.

Sources:

Biotinylated nanoparticles: A new frontier in nanomedicine and targeted cancer therapy. Biomaterials Advances, 2025;176:214366.
NewsRx. Graphic Era Hill University Reports Findings in Cancer (Biotinylated nanoparticles: A new frontier in nanomedicine and targeted cancer therapy). Nanotechnology Weekly. June 16, 2025; p 468.